Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
TAK moved a median of +0.06% 30 minutes after news, and +0.06% by the close. How TAK actually reacts to news — the realized, point-in-time move the market made, measured across 425 labeled events over the last three years with zero look-ahead.
TAK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 425 |
| 30-min | +0.06% | 55% | 425 |
| 60-min | +0.04% | 52% | 425 |
| to close | +0.06% | 51% | 424 |
| Middle 50% of TAK reactions | -0.30% to +0.39% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 425 |
Half of all Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events land between -0.30% and +0.39% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TAK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TAK's baseline. Nothing else.
Recent TAK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 | Press release | Business Wire | +0.35% | +2.04% | |
| Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 | Press release | Business Wire | — | — | |
| Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill | Press release | Business Wire | -0.54% | -1.46% | |
| Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 | Press release | Business Wire | -0.26% | +0.16% | |
| Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems | Press release | Business Wire | +0.64% | +0.58% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | +0.62% | +0.32% | |
| U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations | Press release | Business Wire | +0.62% | +0.32% | |
| New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life | Press release | Business Wire | +0.33% | +0.17% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | -0.14% | -0.06% | |
| Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera | Press release | Business Wire | -0.14% | -0.06% | |
| ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | Press release | Business Wire | -0.60% | +0.00% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Aug 05 | SEC filing · Form 6-K | SEC EDGAR | +0.12% | -0.53% | |
| U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | Press release | Business Wire | +0.12% | -0.53% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jul 30 | SEC filing · Form 6-K | SEC EDGAR | +0.82% | +1.23% | |
| Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track | Press release | Business Wire | +0.82% | +1.23% | |
| Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies | Press release | Business Wire | +0.41% | +1.18% | |
| Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products | Press release | Business Wire | -0.18% | -0.18% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jul 09 | SEC filing · Form 6-K | SEC EDGAR | +0.15% | +0.06% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.18% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | -0.19% | +0.00% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | +0.86% | +1.21% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24 | SEC filing · Form 6-K | SEC EDGAR | -0.25% | -1.13% | |
| Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO | Press release | Business Wire | -0.25% | -1.13% | |
| Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations | Press release | Canada Newswire | -0.19% | +1.21% | |
| Form 20-F TAKEDA PHARMACEUTICAL For: Mar 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -0.39% | |
| Form IRANNOTICE TAKEDA PHARMACEUTICAL | SEC filing · Form IRANNOTICE | SEC EDGAR | +0.00% | -0.39% | |
| New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 | Press release | Business Wire | +0.00% | -0.10% | |
| Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations | Press release | Business Wire | +0.38% | +0.83% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jun 09 | SEC filing · Form 6-K | SEC EDGAR | -0.26% | +0.32% | |
| U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease | Press release | Business Wire | -0.03% | -0.95% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jun 05 | SEC filing · Form 6-K | SEC EDGAR | +0.45% | +0.58% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Jun 01 | SEC filing · Form 6-K | SEC EDGAR | +0.78% | -0.91% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: May 26 | SEC filing · Form 6-K | SEC EDGAR | +0.06% | -0.81% | |
| Form SD TAKEDA PHARMACEUTICAL | SEC filing · Form SD | SEC EDGAR | +0.03% | +0.65% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: May 19 | SEC filing · Form 6-K | SEC EDGAR | -0.18% | +0.24% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: May 13 | SEC filing · Form 6-K | SEC EDGAR | -0.19% | +3.42% | |
| Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results | Press release | Business Wire | -0.19% | +3.42% | |
| British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome | Press release | Canada Newswire | -0.20% | -0.12% | |
| Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) | Press release | Business Wire | +0.72% | +0.06% | |
| Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care | Press release | Canada Newswire | -0.08% | +1.65% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Mar 30 | SEC filing · Form 6-K | SEC EDGAR | -0.06% | +0.39% | |
| Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care | Press release | Business Wire | -0.06% | +0.39% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Mar 26 | SEC filing · Form 6-K | SEC EDGAR | +0.17% | -0.17% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Mar 25 | SEC filing · Form 6-K | SEC EDGAR | +0.05% | -0.43% | |
| Alan Walshe Appointed General Manager of Takeda Canada | Press release | Canada Newswire | -0.35% | -0.05% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Mar 02 | SEC filing · Form 6-K | SEC EDGAR | -0.35% | -0.05% | |
| Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera | Press release | Business Wire | -0.35% | -0.05% | |
| Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis | Press release | Business Wire | +0.11% | +0.51% | |
| Form 6-K TAKEDA PHARMACEUTICAL For: Feb 10 | SEC filing · Form 6-K | SEC EDGAR | +0.42% | +0.56% | |
| U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 | Press release | Business Wire | +0.42% | +0.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TAK section they belong to.
Where else TAK is measured.
TAK earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)'s median reaction calculated?
Every labeled TAK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 425 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of TAK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TAK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.